Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Cash from Investing Activities (2023 - 2025)

CG Oncology filings provide 3 years of Cash from Investing Activities readings, the most recent being -$75.5 million for Q4 2025.

  • On a quarterly basis, Cash from Investing Activities fell 792.39% to -$75.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$245.8 million, a 18.27% increase, with the full-year FY2025 number at -$245.8 million, up 18.27% from a year prior.
  • Cash from Investing Activities hit -$75.5 million in Q4 2025 for CG Oncology, down from $15.0 million in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $103.4 million in Q2 2023 to a low of -$307.4 million in Q1 2024.
  • Median Cash from Investing Activities over the past 3 years was -$17.4 million (2024), compared with a mean of -$55.6 million.
  • Biggest five-year swings in Cash from Investing Activities: surged 119.83% in 2024 and later plummeted 792.39% in 2025.
  • CG Oncology's Cash from Investing Activities stood at $15.5 million in 2023, then decreased by 29.8% to $10.9 million in 2024, then plummeted by 792.39% to -$75.5 million in 2025.
  • The last three reported values for Cash from Investing Activities were -$75.5 million (Q4 2025), $15.0 million (Q3 2025), and $1.4 million (Q2 2025) per Business Quant data.